Wednesday, February 14, 2024 8:52:58 PM
Pfizer Inc came out with Lyrica
Pregabalin (Lyrica) is a medication that treats nerve pain by calming overactive nerves.
It can also treat epilepsy.
Pfizer transferred Lyrica to Viastris Inc
Here is promising Drug Company for Epilepsy
$RSPI .0013
RespireRx Pharmaceuticals Ticker: RSPI
Is working on Revolutionary New Hope:
KRM-II-81 Drug-Resistant Epilepsy Patients
Link found on National Library of Medicine
The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders
https://pubmed.ncbi.nlm.nih.gov/35041859/
https://www.neurexplain.com/2024/01/17/revolutionary-krm-ii-81-a-new-hope-for-drug-resistant-epilepsy-patients/
National Institutes of Health
A clinical case of a 19-year-old male patient with pharmacoresistant seizures occurring following parieto-occipital tumor-resection at age 6 ...
KRM–II–81 suppresses epileptifom activity across the neural network of cortical tissue from a patient with pharmacoresistant epilepsy
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10784158/
The value of human epileptic tissue in the characterization and development of novel antiepileptic drugs: The example of CERC-611 and KRM-II-81
https://www.sciencedirect.com/science/article/abs/pii/S000689931930410X
Pregabalin (Lyrica) is a medication that treats nerve pain by calming overactive nerves.
It can also treat epilepsy.
Pfizer transferred Lyrica to Viastris Inc
Here is promising Drug Company for Epilepsy
$RSPI .0013
RespireRx Pharmaceuticals Ticker: RSPI
Is working on Revolutionary New Hope:
KRM-II-81 Drug-Resistant Epilepsy Patients
Link found on National Library of Medicine
The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders
https://pubmed.ncbi.nlm.nih.gov/35041859/
https://www.neurexplain.com/2024/01/17/revolutionary-krm-ii-81-a-new-hope-for-drug-resistant-epilepsy-patients/
National Institutes of Health
A clinical case of a 19-year-old male patient with pharmacoresistant seizures occurring following parieto-occipital tumor-resection at age 6 ...
KRM–II–81 suppresses epileptifom activity across the neural network of cortical tissue from a patient with pharmacoresistant epilepsy
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10784158/
The value of human epileptic tissue in the characterization and development of novel antiepileptic drugs: The example of CERC-611 and KRM-II-81
https://www.sciencedirect.com/science/article/abs/pii/S000689931930410X
Recent VTRS News
- Viatris Announces Several Data Presentations on Investigational Low-Dose Estrogen Combined Hormonal Contraceptive Weekly Patch at the 2026 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Meeting • PR Newswire (US) • 05/01/2026 10:59:00 AM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/30/2026 06:24:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/16/2026 10:00:28 PM
- Viatris to Report First Quarter 2026 Financial Results on May 7, 2026 • PR Newswire (US) • 04/13/2026 10:59:00 AM
- Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting • PR Newswire (US) • 04/10/2026 10:59:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/02/2026 08:31:39 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/02/2026 08:30:52 PM
- Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD) • PR Newswire (US) • 03/23/2026 10:59:00 AM
- Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030 • PR Newswire (US) • 03/19/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/10/2026 11:04:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/10/2026 11:03:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 12:00:19 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 12:00:17 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 12:00:16 AM
- Viatris tops forecasts as earnings and revenue beat expectations • IH Market News • 02/26/2026 02:45:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 12:52:59 PM
- Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results • PR Newswire (US) • 02/26/2026 11:59:00 AM
- Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend • PR Newswire (US) • 02/26/2026 11:55:00 AM
- FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia • PR Newswire (US) • 02/25/2026 11:59:00 AM
- Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026 • PR Newswire (US) • 02/03/2026 09:34:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/03/2026 09:30:31 PM
- Viatris Appoints Matthew J. Maletta as Chief Legal Officer • PR Newswire (US) • 02/03/2026 01:30:00 PM
- Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure • PR Newswire (US) • 01/20/2026 11:59:00 AM
